启膈散加减方联合TS化疗方案治疗中晚期食管鳞癌的临床疗效及安全性  

Clinical Efficacy and Safety of Qige Pulvis Plus Minus Formula combined with TS Chemotherapy in the Treatment of Middle and Advanced Esophageal Squamous Carcinoma

作　　者：冒德芳 邱美林 姜晓敏 金凤 MAO De-Fang;QIU Mei-Lin;JIANG Xiao-Min;JIN Feng(Department of Spleen and Stomach,Yangzhou Hospital of Traditional Chinese Medicine,Yangzhou 225009,China;Traditional Chinese Dedicine Department of Yangzhou Jiangdu Maternal and Child Health Hospital,Yangzhou 225200,China;Medical School of Yangzhou University,Yangzhou 225009,China;Department of Respiratory and Critical Care Medicine,Afiliated Hospital of Yangzhou University,Yangzhou 225009,China)

机构地区：[1]扬州市中医院脾胃科,江苏扬州1225009 [2]扬州市江都妇幼保健院中医科,江苏扬州1225200 [3]扬州大学医学院,江苏扬州225009 [4]扬州大学附属医院呼吸与危重症医学科,江苏扬州225009

出　　处：《中国药物经济学》2024年第4期76-80,共5页China Journal of Pharmaceutical Economics

基　　金：国家自然科学基金青年项目(81903850);江苏省中医药管理局项目(YB201992)。

摘　　要：目的探讨启膈散加减方联合TS化疗方案治疗中晚期食管鳞癌(ESCC)的临床疗效及安全性。方法选取2019年1月至2022年6月于扬州市中医院诊治的80例中晚期ESCC患者为研究对象,采用随机分组的方法分为对照组与观察组,各40例。对照组给予TS方案化疗,观察组在对照组基础上采用启膈散加减方治疗。比较两组患者临床疗效、中医证候积分、血清肿瘤标志物水平、不良反应。结果观察组治疗有效率为90.0%,明显高于对照组的72.5%(P<0.05)。治疗后两组吞咽困难、疼痛、声音嘶哑、食欲减退、消瘦乏力、呕吐涎沫评分较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清鳞状细胞癌抗原(SSCAg)水平低于治疗前,且观察组血清SSCAg水平低于对照组,差异有统计学意义(P<0.05);两组血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原724(CA724)水平组内及组间比较差异无统计学意义(P>0.05)。两组治疗后不良反应发生率比较差异无统计学意义(P>0.05)。结论启膈散加减方联合TS化疗方案治疗ESCC临床疗效显著,可有效改善临床症状,且安全性较高。Objective To explore the clinical efficacy and safety of Qige pulvis plus minus formula combined with TS chemotherapy in the treatment of advanced esophageal squamous cell carcinoma(ESCC).Methods Eighty patients with advanced ESCC treated and treated in Yangzhou Hospital of Traditional Chinese Medicine from January 2019 to June 2022 were selected as the study objects,and were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with TS chemotherapy,and the observation group was treated with Qige pulvis plus minus formula on the basis of the control group.The clinical efficacy,TCM syndrome score,serum tumor marker level and adverse reactions were compared between the two groups.ResultsThe effective rate of the observation group was 90.0%,which was significantly higher than that of the control group(72.5%)(P<0.05).After treatment,the scores of dysphagia,pain,hoarseness,loss of appetite,emaciation,and saliva vomiting in the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,serum squamous cell carcinoma antigen(SSCAg)level in 2 groups was lower than before treatment,and serum SSCAg level in observation group was lower than control group,the difference was statistically significant(P<0.05).There was no significant difference in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)and carbohydrate antigen 724(CA724)between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion Qige pulvis plus minus formula combined with TS chemotherapy has significant clinical efficacy in the treatment of ESCC,and can effectively improve clinical symptoms with high safety.

关 键 词：食管鳞癌 联合治疗 启膈散 化疗 

分 类 号：R735.1[医药卫生—肿瘤] R289.5[医药卫生—临床医学]